This is a linkpost for https://www.1daysooner.org/how-cost-effective-is-the-new-r21-vaccine-compared-to-existing-malaria-interventions/
This detailed analysis by Karam Elabd and Ryan Duncombe, PhD, evaluates the cost-effectiveness of the new R21 malaria vaccine in comparison to other existing interventions such as insecticide-treated bed nets (ITNs), seasonal malaria chemoprevention (SMC), and mosquito control. They crunched the data into 2024 US dollars and found that the R21 vaccine is just about as cost-effective as those trusty bed nets.
1. Cost-Effectiveness Comparison:
- The R21 vaccine has a cost per disability-adjusted life year (DALY) averted of $39.
- Insecticide-treated bed nets (ITNs) have a cost per DALY averted of $38.
2. Delivering a Year of Healthy Life for Less Than $50:
- Both the R21 vaccine and ITNs deliver a year of healthy life for less than $50, as their cost per DALY averted (less than $40) falls well within this range.